155 related articles for article (PubMed ID: 20012716)
1. Backbone assignments of the 26 kDa neuron-specific ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1).
Andersson FI; Jackson SE; Hsu ST
Biomol NMR Assign; 2010 Apr; 4(1):41-3. PubMed ID: 20012716
[TBL] [Abstract][Full Text] [Related]
2. Backbone 1H, 13C, and 15N resonance assignments for the 26-kD human de-ubiquitinating enzyme UCH-L3.
Harris R; Eidhoff U; Vinzenz D; Renatus M; Gerhartz B; Hommel U; Driscoll PC
Biomol NMR Assign; 2007 Jul; 1(1):51-3. PubMed ID: 19636824
[TBL] [Abstract][Full Text] [Related]
3. Backbone and side-chain 1H, 15N and 13C resonance assignments of S18Y mutant of ubiquitin carboxy-terminal hydrolase L1.
Tse HS; Hu HY; Sze KH
Biomol NMR Assign; 2011 Oct; 5(2):165-8. PubMed ID: 21298373
[TBL] [Abstract][Full Text] [Related]
4. Substrate recognition and catalysis by UCH-L1.
Luchansky SJ; Lansbury PT; Stein RL
Biochemistry; 2006 Dec; 45(49):14717-25. PubMed ID: 17144664
[TBL] [Abstract][Full Text] [Related]
5. Endogenous neurotoxic dopamine derivative covalently binds to Parkinson's disease-associated ubiquitin C-terminal hydrolase L1 and alters its structure and function.
Contu VR; Kotake Y; Toyama T; Okuda K; Miyara M; Sakamoto S; Samizo S; Sanoh S; Kumagai Y; Ohta S
J Neurochem; 2014 Sep; 130(6):826-38. PubMed ID: 24832624
[TBL] [Abstract][Full Text] [Related]
6. Characterization of multimetric variants of ubiquitin carboxyl-terminal hydrolase L1 in water by small-angle neutron scattering.
Naito S; Mochizuki H; Yasuda T; Mizuno Y; Furusaka M; Ikeda S; Adachi T; Shimizu HM; Suzuki J; Fujiwara S; Okada T; Nishikawa K; Aoki S; Wada K
Biochem Biophys Res Commun; 2006 Jan; 339(2):717-25. PubMed ID: 16316632
[TBL] [Abstract][Full Text] [Related]
7. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants.
Nishikawa K; Li H; Kawamura R; Osaka H; Wang YL; Hara Y; Hirokawa T; Manago Y; Amano T; Noda M; Aoki S; Wada K
Biochem Biophys Res Commun; 2003 Apr; 304(1):176-83. PubMed ID: 12705903
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron.
Osaka H; Wang YL; Takada K; Takizawa S; Setsuie R; Li H; Sato Y; Nishikawa K; Sun YJ; Sakurai M; Harada T; Hara Y; Kimura I; Chiba S; Namikawa K; Kiyama H; Noda M; Aoki S; Wada K
Hum Mol Genet; 2003 Aug; 12(16):1945-58. PubMed ID: 12913066
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1.
Das C; Hoang QQ; Kreinbring CA; Luchansky SJ; Meray RK; Ray SS; Lansbury PT; Ringe D; Petsko GA
Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4675-80. PubMed ID: 16537382
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitin dimers control the hydrolase activity of UCH-L3.
Setsuie R; Sakurai M; Sakaguchi Y; Wada K
Neurochem Int; 2009; 54(5-6):314-21. PubMed ID: 19154770
[TBL] [Abstract][Full Text] [Related]
11. Production of polyclonal anti-dUCH (Drosophila ubiquitin carboxyl-terminal hydrolase) antibodies.
Tram NT; Trang NT; Thao DT; Thuoc TL
Monoclon Antib Immunodiagn Immunother; 2013 Apr; 32(2):105-12. PubMed ID: 23607345
[TBL] [Abstract][Full Text] [Related]
12. Parkinson's disease-associated mutations in α-synuclein and UCH-L1 inhibit the unconventional secretion of UCH-L1.
Konya C; Hatanaka Y; Fujiwara Y; Uchida K; Nagai Y; Wada K; Kabuta T
Neurochem Int; 2011 Aug; 59(2):251-8. PubMed ID: 21693148
[TBL] [Abstract][Full Text] [Related]
13. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA
J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitin recognition of BAP1: understanding its enzymatic function.
Hanpude P; Bhattacharya S; Kumar Singh A; Kanti Maiti T
Biosci Rep; 2017 Oct; 37(5):. PubMed ID: 28935764
[TBL] [Abstract][Full Text] [Related]
15. Cloning and expression analysis of a Parkinson's disease gene, uch-L1, and its promoter in zebrafish.
Son OL; Kim HT; Ji MH; Yoo KW; Rhee M; Kim CH
Biochem Biophys Res Commun; 2003 Dec; 312(3):601-7. PubMed ID: 14680807
[TBL] [Abstract][Full Text] [Related]
16. Glutathione-mediated reversibility of covalent modification of ubiquitin carboxyl-terminal hydrolase L1 by 1,2-naphthoquinone through Cys152, but not Lys4.
Toyama T; Shinkai Y; Yazawa A; Kakehashi H; Kaji T; Kumagai Y
Chem Biol Interact; 2014 May; 214():41-8. PubMed ID: 24582816
[TBL] [Abstract][Full Text] [Related]
17. [The ubiquitin-proteasome system and neurodegeneration].
Wada K; Osaka H; Aoki S; Wang YL
Rinsho Shinkeigaku; 2001 Dec; 41(12):1072-4. PubMed ID: 12235799
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitin C-terminal hydrolase L1 (UCH-L1): structure, distribution and roles in brain function and dysfunction.
Bishop P; Rocca D; Henley JM
Biochem J; 2016 Aug; 473(16):2453-62. PubMed ID: 27515257
[TBL] [Abstract][Full Text] [Related]
19. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases.
Choi J; Levey AI; Weintraub ST; Rees HD; Gearing M; Chin LS; Li L
J Biol Chem; 2004 Mar; 279(13):13256-64. PubMed ID: 14722078
[TBL] [Abstract][Full Text] [Related]
20. Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders.
Lee YC; Hsu SD
Curr Protein Pept Sci; 2017; 18(7):733-745. PubMed ID: 26899237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
